AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01703455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
Study NCT00275093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00275093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00275093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02959060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Single dose of BMS-986177 and multiple doses of Rifampin
Study NCT02959060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Single dose of BMS-986177 and multiple doses of Rifampin
Study NCT01404312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets).
Study NCT01404312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (INH)
Description: Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
Study NCT01404312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
Study NCT01404312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH.
Study NCT01404312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH.
Study NCT04040803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)
Description: Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
Study NCT04040803 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)
Description: Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
Study NCT04000451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen
Description: Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
Study NCT04000451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
Study NCT04000451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
Study NCT01097135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duraprep Surgical Solution
Study NCT04477980 — intervention group
Intervention type: OTHER
Intervention: Disease outcome (mortality)
Description: Mortality rate between the two groups
Study NCT00158379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
Study NCT01868581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
Study NCT01868581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
Study NCT04514315 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive cardiac valvular surgery
Description: Minimally invasive valve surgery via right mini-thoracotomy.
Study NCT04514315 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional cardiac valvular surgery
Description: Conventional valve surgery via full median sternotomy
Study NCT05684016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NeuroQuant
Description: Reliably defines the volume of those parts of the brain that are important for memory and thinking.
Study NCT05684016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Neuropsychological Assessment Matrices
Description: This is like an IQ test.
Study NCT05684016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDSS
Description: Extended Disability Status Score
Study NCT05684016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Physical Examination
Study NCT01230593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hot Compress plus Tobramycin Drops and Ointment
Description: In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
Study NCT01230593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hot compress plus Tobramycin/Dexamethasone Drops and Ointment
Description: In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
Study NCT01230593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Compresses
Description: Hot compresses 3x/day to eyelids
Study NCT03809182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
Study NCT03809182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: The same infusion rate used in the dexmedetomidine group.
Study NCT03809182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
Study NCT03809182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
Study NCT03809182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine Sulfate
Description: Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
Study NCT03809182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
Study NCT01169870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
Study NCT01169870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT04015648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 Zika
Description: Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
Study NCT00903591 — intervention group
Intervention type: OTHER
Intervention: questionaire, blood or saliva sample
Description: Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
Study NCT02527616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR Infusion Microcatheter and standard intra-venous (IV) infusion
Description: Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
Study NCT02622503 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
Study NCT02008331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYNBIOTIC
Description: INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
Study NCT02529085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples for the bank
Study NCT02529085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples for the bank
Study NCT01952639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
Study NCT01952639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein type and amount
Description: Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
Study NCT02405715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray or placebo
Study NCT02405715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray or placebo
Study NCT03873649 — intervention group
Intervention type: OTHER
Intervention: Bronchoscopy with lavage
Description: Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response.
Study NCT04133610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampling using digene HC2 DNA Collection Device
Description: All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
Study NCT04133610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampling using Evalyn Brush
Description: All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
Study NCT03935386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Multi-layered Compression dressing
Description: Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
Study NCT03935386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)
Description: Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
Study NCT02181530 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) is being administered as part of this study.
Study NCT01561118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle-Ergometer Training
Description: Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis.
Study NCT01141894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed haemodynamic treatment
Description: Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
Study NCT01141894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine fluid treatment
Description: Protocol guided fluid treatment used in the clinical routine
Study NCT02357212 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary angiography
Description: invasive procedure performed to determine coronary anatomy
Study NCT02357212 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: adenosine stress test
Description: non-invasive procedure to determine area of cardiac ischemia
Study NCT03606759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weekly assessment ajusted
Description: Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)
Study NCT04143802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC
Study NCT04143802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT04143802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03012321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Study NCT03012321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Study NCT03921268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
Study NCT01561118 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bicycle-Ergometer Training
Description: Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis.
Study NCT00678379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine (1%) + bupivacaine (0.5%)
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)
Study NCT03721380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
Study NCT03721380 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
Study NCT01735539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g EAA bolus
Description: Oral; in aqueous solution
Study NCT03012321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT00113334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-510
Description: 100 mg subcutaneously twice daily
Study NCT05444777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine was given prior to wound closure.
Study NCT05444777 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine Hydrochloride
Description: Ketamine was given prior to wound closure.
Study NCT03441789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Enstilar foam applied to affected areas daily
Study NCT03441789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: vehicle foam applied to affected areas once daily
Study NCT03441789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otezla
Description: Otezla 30mg
Study NCT03441789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Otezla
Description: Otezla 30mg
Study NCT03508882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 100Unit/Vial (Product)
Description: Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
Study NCT03508882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution for Injection
Description: The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
Study NCT03661749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clean catch
Description: clean catch technique applied to collect urine for PR/CR ratio
Study NCT00678379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline